首页 › 基金 › ACT Capital Partners, L.P. › ARWR

ACT Capital Partners, L.P. 对 ARWR 的持仓历史

ARROWHEAD PHARMACEUTICALS IN · 医疗保健

ACT Capital Partners, L.P. 在 Q3 2026 的 13F 申报中披露持有 ARWR(ARROWHEAD PHARMACEUTICALS IN)94,000 股,市值约 US$6.2M,约占其申报组合的 4.17%,在其申报持仓中市值排名第 9 位。 ACT Capital Partners, L.P. 于 Q3 2026 首次申报该持仓。

最新持仓 (Q3 2026)94.00K 股
申报持仓市值$6.15M
组合权重4.17%
首次申报Q3 2026
最近变动新进
更新于2026-11-07

最后更新: 2026-11-07 · 来源: SEC EDGAR Form 13F-HR

ACT Capital Partners, L.P. 对 ARWR 的持仓演变

ACT Capital Partners, L.P. 于 Q3 2026 首次披露 ARWR 持仓:94,000 股(约 US$6.2M)。

逐季持仓明细

季度股数金额变化
Q3 2026 94.00K $6.15M 新进

关于 ARWR 与 13F 数据

ARWR(ARROWHEAD PHARMACEUTICALS IN)属于医疗保健行业。我们追踪的基金中还有 53 只申报持有 ARWR,申报仓位最大的包括:Avoro Capital Advisors LLC (US$925.6M), FRED ALGER MANAGEMENT, LLC (US$269.1M), BAKER BROS. ADVISORS LP (US$162.4M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。

其它持有 ARWR 的基金

查看 ARWR 的全部基金持有人 →

常见问题

How long has ACT Capital Partners, L.P. held ARWR?

ACT Capital Partners, L.P. has disclosed ARWR holdings in 1 of the last 1 reported quarters, going back to Q3 2026.

What is ACT Capital Partners, L.P.'s current position in ARWR?

As of Q3 2026, ACT Capital Partners, L.P. holds 94.00K shares of ARWR (ARROWHEAD PHARMACEUTICALS IN), valued at $6.15M, representing 4.17% of its reported portfolio and ranking #9.

Has ACT Capital Partners, L.P. been buying or selling ARWR?

In the latest 13F filing (Q3 2026), ACT Capital Partners, L.P. newly opened its position in ARWR.

Which other funds hold ARWR?

Other major institutional holders of ARWR include Avoro Capital Advisors LLC, FRED ALGER MANAGEMENT, LLC, BAKER BROS. ADVISORS LP, among 53 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.